MARKET

RGLS

RGLS

Regulus Therapeu
NASDAQ
1.690
+0.010
+0.60%
Opening 15:38 11/28 EST
OPEN
1.660
PREV CLOSE
1.680
HIGH
1.762
LOW
1.630
VOLUME
23.50K
TURNOVER
36.71K
52 WEEK HIGH
4.194
52 WEEK LOW
1.330
MARKET CAP
28.46M
P/E (TTM)
-0.7945
1D
5D
1M
3M
1Y
5Y
BRIEF-Regulus Therapeutics Reports Third Quarter 2022 Financial Results And Recent Updates
Reuters · 11/10 21:22
Regulus Therapeutics GAAP EPS of -$0.50
Seekingalpha · 11/10 21:20
Regulus Therapeutics Q3 EPS $(0.50) Misses $(0.49) Estimate
Benzinga · 11/10 21:13
Notable earnings after Thursday's close
Seekingalpha · 11/09 22:35
Earnings Outlook For Regulus Therapeutics
Benzinga · 11/09 19:04
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/08 12:11
Canaccord Genuity Initiates Coverage On Regulus Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga · 11/08 09:57
--Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target
--Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target
MT Newswires · 11/08 08:49
More
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s product lead product candidates include RG-012 and RGLS8429. The Company is focused on evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). The Company also focuses on the evaluation of its designed compounds that inhibit miR-155 activity in microglia cell-based assays and in animal models of the disease, to identify potential candidates to advance into further studies. In addition to its focus on genetic kidney disease, the Company is focused on the research in technology to treat central nervous system (CNS) disease.

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.